# Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

> **NCT01300429** · — · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **GENETIC:** obtain tissue specimens

## Key facts

- **NCT ID:** NCT01300429
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-08
- **Primary completion:** 2021-01-05
- **Final completion:** 2021-01-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300429, "Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01300429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*